DNA-directed RNA interference

American Lung Association, Gateway for Cancer Research Partner to Develop Personalized Lung Cancer Vaccine

Retrieved on: 
Wednesday, May 3, 2023

 CHICAGO, May 3, 2023 /PRNewswire/ -- Gateway for Cancer Research, a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the world, today announced a new partnership with the American Lung Association Research Institute. The alliance centers on a funding agreement between Gateway and the Lung Association to advance a personalized vaccine trial that aims to train each patient's immune system to combat small cell lung cancer (SCLC). Spearheaded by Jeffrey Ward, MD, PhD, a medical oncologist at Washington University School of Medicine in St. Louis, Missouri, the trial officially began enrolling patients in spring 2022 for what will be a five-year study. Investigators believe it to be the only ongoing trial integrating a personalized vaccine into first-line therapy for SCLC.

Key Points: 
  • CHICAGO, May 3, 2023 /PRNewswire/ -- Gateway for Cancer Research , a nonprofit organization dedicated to funding transformational early phase cancer clinical trials around the world, today announced a new partnership with the American Lung Association Research Institute .
  • The alliance centers on a funding agreement between Gateway and the Lung Association to advance a personalized vaccine trial that aims to train each patient's immune system to combat small cell lung cancer (SCLC).
  • An aggressive type of lung cancer, SCLC is estimated to account for approximately 14% of all lung cancer diagnoses.
  • Gateway for Cancer Research and the American Lung Association together have contributed $678,668 to support development of the trial vaccine.

U.S. Gene Editing Market Report 2022: Diversified Application Areas of Gene Editing Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 22, 2022

The U.S. gene editing market is expected to grow at a CAGR of 21.13% during 2022-2027.

Key Points: 
  • The U.S. gene editing market is expected to grow at a CAGR of 21.13% during 2022-2027.
  • Unlike genetic engineering, which randomly incorporates genetic material into the host genome, gene editing aims to make changes at specific target locations.
  • Genome editing technology is a technique for target gene modification that allows the knockout and addition of specific fragments of DNA.
  • These are some of the factors that are boosting the growth of the U.S. gene editing market.

DGAP-News: Defence Therapeutics Inc.: BREAKTHROUGH DISCOVERY: ACCUTOXTM EFFECTIVELY KILLS CANCER CELLS BY DIRECTLY ELICITING DNA DAMAGE

Retrieved on: 
Tuesday, August 2, 2022

Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this.

Key Points: 
  • Although it is difficult to reactivate these specific pathways to elicit cancer cell death, AccuTOXTM can address this.
  • Defence previously reported (see press release of June 22, 2021) the discovery of an AccumTM variant, AccuTOXTM, capable of controlling cancer growth when injected directly in tumors.
  • "Defences breakthrough discovery with its AccuTOXTM formulation as a novel potent small molecule capable of killing cancer cells is a significant advancement and development for oncology cancer treatment applications with AccumTM.
  • Defence is currently conducting GLP studies on AccuTOXTM prior to initiate a Phase I trial in North America.

Fusion Pharmaceuticals and Niowave Announce Actinium-225 Collaboration and Supply Agreement

Retrieved on: 
Friday, June 10, 2022

As part of the agreement, Fusion will also have an option to invest in future production of actinium-225 to scale with Fusion's needs.

Key Points: 
  • As part of the agreement, Fusion will also have an option to invest in future production of actinium-225 to scale with Fusion's needs.
  • Fusion currently has existing actinium supply arrangements with TRIUMF and the U.S. Department of Energy (DOE).
  • Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
  • Niowave is a Cooperative Agreement partner with the National Nuclear Security Administration to develop a domestic supply of molybdenum-99 and currently produces yttrium-90 for use in cancer therapy.